Research programme: degenerative and metabolic disorder therapeutics - Prothena Corporation

Drug Profile

Research programme: degenerative and metabolic disorder therapeutics - Prothena Corporation

Alternative Names: Islet amyloid polypeptide antibodies - Prothena; PRX 004

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neotope Biosciences
  • Developer Neotope Biosciences; Prothena
  • Class Eye disorder therapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyloidosis; Metabolic disorders; Neurodegenerative disorders
  • Research Age-related macular degeneration

Most Recent Events

  • 16 Nov 2017 Prothena Corporation plans a phase I trial for Amyloidosis by mid-2018
  • 24 Feb 2017 Prothena has patent protection for PRX 004 (Prothena's form 10-K, filed in February 2017)
  • 16 Mar 2016 Preclinical development in Amyloidosis is ongoing Ireland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top